AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06707818 — intervention group
Intervention type: OTHER
Intervention: Intraoperative Interventions
Description: All surgical procedures will follow the standard general anesthesia protocol of the hospital. General anesthesia induction will involve propofol (1-2 mg/kg), fentanyl (1 mcg/kg), and rocuronium (0.6 mg/kg) for endotracheal intubation. Anesthesia maintenance will be performed with desflurane (4-6%) and remifentanil (0.1 mcg/kg/min), with adjustments as needed based on blood pressure and heart rate. Post-induction, dexamethasone (4 mg) will be administered for anti-inflammatory effects. To support postoperative pain management, tramadol (1 mg/kg), ibuprofen (400 mg), and paracetamol (1 g) will be administered before the end of the procedure. Ondansetron (4 mg) will be used for nausea prophylaxis. All intraoperative medications and dosages will be recorded without intervention.
Study NCT05759611 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard integrated metabolic rehabilitation protocol + specific respiratory muscle training program
Description: Physical exercise protocol before and after 12 sessions of standard integrated metabolic rehabilitation protocol + a specific respiratory muscle training program according to the protocol recently proposed by Spengler et al. (Wuthrich et al., 2015; Schaer et al., 2018), adapted according to the baseline characteristics of the respiratory function of the subjects.
Study NCT05983588 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAVICTI 1.1 g/ml
Description: Duration of Treatment: 26 weeks, twice daily~Dosage:~* weeks 0 - 3: 3 ml/day (1,5ml - 0 - 1,5ml) (≙ 3,3 g glycerol phenylbutyrate/placebo)~* weeks 4 - 26: 6 ml/day (3 ml - 0 - 3 ml) (≙ 6,6 g glycerol phenylbutyrate/placebo)
Study NCT05983588 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Duration of Treatment: 26 weeks, twice daily~Dosage:~* weeks 0 - 3: 3 ml/day (1,5ml - 0 - 1,5ml) (≙ 3,3 g glycerol phenylbutyrate/placebo)~* weeks 4 - 26: 6 ml/day (3 ml - 0 - 3 ml) (≙ 6,6 g glycerol phenylbutyrate/placebo)
Study NCT06707818 — intervention group
Intervention type: OTHER
Intervention: Postoperative Interventions
Description: In the recovery room, analgesic interventions will follow the hospital's standard protocol: patients with VAS scores between 3 and 7 will receive 25 mcg of fentanyl, while those with scores above 7 will receive 50 mcg.~All patients will receive standard multimodal analgesia during the ward stay, including paracetamol (1 g, three times daily) and ibuprofen (400 mg, twice daily). Patient-controlled analgesia (PCA) devices will administer tramadol (10 mg IV per patient request, without continuous infusion).
Study NCT06709209 — intervention group
Intervention type: PROCEDURE
Intervention: Colonoscopy after bowel cleansing
Description: Colonoscopy will be performed using HD-WLE; TXI; RDI and NBI.
Study NCT06709209 — intervention group
Intervention type: PROCEDURE
Intervention: Intestinal biopsies
Description: During colonoscopy, at least 2 biopsies from each segment will be taken as standard of care to assess inflammation in UC
Study NCT06709209 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: blood sampling
Description: Blood samples will be taken for standard of care by appropriately trained members of the clinical research team. The results of the standard of care blood will be used in the research.
Study NCT06709209 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Stool
Description: The stool sample will be sent to the laboratory for Faecal Calprotectin (FCP) as a marker of disease activity.
Study NCT06709209 — intervention group
Intervention type: OTHER
Intervention: Clinical follow-up
Description: Patients will be followed-up at 6 and 12 months after index endoscopy. Patients will be evaluated in clinic or by telephone call and the disease will be reassessed. Partial Mayo Score (PMS) and occurrence of clinical outcomes will be evaluated.
Study NCT04973111 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CT-868 as SC Injection
Description: CT-868
Study NCT04973111 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo as SC Injection
Description: Placebo
Study NCT04973111 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator as SC Injection
Description: Active Comparator
Study NCT05323786 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: The combined topical anesthesia induction group
Description: Inhalation of aerosolized surface anesthesia with 10 ml 2% lidocaine would be administered with an atomizer for 15 minutes prior to intravenous anesthesia. After the intravenous induction, a catheter would be inserted to provide the subglottic anesthesia with 3ml 2% lidocaine.
Study NCT05323786 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: The routine induction group
Description: Inhalation of 10 ml 0.9% normal saline would be administered with an atomizer for 15 minutes prior to intravenous anesthesia. After the intravenous induction, 3ml 0.9% normal saline would be administered into subglottic airway with a catheter.
Study NCT06235463 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Osteopathic Pedal Pump
Description: Participants randomized to this condition will receive 5 minutes of myofascial release to the thoracic inlet and 5 minutes of the pedal pump technique.
Study NCT06235463 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Light Touch Treatment
Description: Participants randomized to receive the sham treatment will receive light touch from the operator on the base of the neck and the balls of the feet. This light touch is meant to mimic the pedal pump through touching the same areas of the body but without palpating so that no lymphatic fluid is removed from the lower limbs.
Study NCT05903339 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3M-052-AF 5mcg
Description: (5 mcg)
Study NCT05903339 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alum 500 mcg
Description: (500 mcg)
Study NCT05903339 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: V3G CH848 mRNA-Tr2 50mcg
Description: (50 mcg)
Study NCT05903339 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACU-026-001-1 2.0mg
Description: (2.0 mg)
Study NCT06641739 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: laser assisted SPPF
Description: A full-thickness flaps were elevated. In the test sites after the SPPF access will be performed, root surface debridement will be meticulously performed, followed by intra-marrow penetrations (IMPs), on the defect walls using a 0.25 mm wide half round bur, mounted on a slow-speed handpiece. Following this, low-level laser biostimulation of the defect will be effected with an 940 nm diode laser at 3 W power, with an uninitiated 0.6mm optical fiber tip. The defects will be irradiated for 20 seconds in a continuous noncontact mode and then retracted for 8 seconds. This will be repeated for 3 times so that the defects were effectively lased for about 60 seconds.
Study NCT06641739 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Platelet Rich Plasma
Description: In the second group, following the SPPF, the defect will grafted with particulated PRF, which will be overlaid with a PRF membrane, without any adjunctive defect management measures. PRF will be prepared by collecting Intra-venous blood (from the antecubital vein) in a 10-ml sterile glass tube without anticoagulant and immediately centrifuged in a centrifugation machine at 3000 rpm for 10 minutes. It will result in the separation of blood into a structured fibrin matrix in the middle of the tube, just between the red corpuscles at the bottom and acellular plasma (platelet poor plasma) at the top. PPP will be discarded. PRF will be easily separated from the red corpuscles base using sterile tweezers and scissors.
Study NCT06712238 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: NB-UVB
Description: Comparison between serum Level of Gelsolin (GSN) in Psoriatic Patients and controls and correlate its level with PASI.
Study NCT06712433 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2% intranasal mupirocin ointment
Description: Mupirocin nasal ointment is used to treat or prevent infections in the nose due to certain strains of Staphylococcus aureus bacteria. This medicine works by killing bacteria or preventing their growth.
Study NCT06712433 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4% chlorhexidine gluconate body cleanser
Description: Chlorhexidine Gluconate (CHG) Solution Antiseptic Skin Cleanser solution is a topical skin cleanser that keeps working after it is used. CHG is a strong antiseptic (liquid used to kill germs and bacteria) that lowers the risk of infection.
Study NCT06713122 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: İntervention Group- Group receiving Symptom Management Training with Mobile Application
Description: The application to be developed in the research will be both Android and IOS supported.~Monitoring the active use of the patients from the interface by the researcher and receiving individual and collective notifications in line with the profile that the patients receiving chemotherapy will create in the application will increase the usability of the application. Thus, the benefit that users receive after active use can be determined.~The content of the Let's fight the symptoms together module will be created by experts in the field and people will be able to actively use these methods while struggling with the symptoms they experience.~Patients may not always have the opportunity to reach a nurse or health professional. In symptom management with the mobile application, artificial intelligence will be trained by the researcher and integrated into the application will help patients reach the right information without wasting time.
Study NCT06714422 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: apple group
Description: Doctors will bring apples during night shift
Study NCT06714422 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: no apple group
Description: No apples during night shift
Study NCT06714500 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LuxValve PLlus
Description: The LuX-Valve (Jenscare Biotechnology) is a radial force-independent orthotopic TTVR device. The feasibility and efficacy of this device have been reported by several studies (11-13). However, this valve was implanted through right atrial access, where a small incision of the right chest and right atrium is needed. The LuX-Valve Plus valve replacement system is the second-generation version of the LuX-Valve and can be implanted through the jugular vein.
Study NCT06712108 — intervention group
Intervention type: PROCEDURE
Intervention: tranplant
Description: double unit cord blood transplnat
Study NCT06711432 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norepinephrine or phenylephrine
Description: Intraoperative use of norepinephrine or phenylephrine (norepinephrine 0.01-0.1ug/kg/min, or phenylephrine 0.15-1.1 ug/kg/min). The actual infusion speed depends on reaching the target MAP(>=80mmHg).
Study NCT06709911 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Basic Manipulation Stretching
Description: This group received standard hand tenosynovitis stretching therapy, which focused on the flexor and extensor muscle groups of the wrist and hand for release. Muscle tension and tendon adhesions were relieved by basic stretching maneuvers, with each intervention lasting 20-30 minutes, twice a week, over a 4- to 8-week period.
Study NCT06709911 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Massage and Tui Na Manipulation
Description: The group received Tui Na manipulation interventions, including pointing, pressing and rolling techniques for the tendon sheath and thumb region, focusing on the stimulation of acupoints such as Hegu, Yangchi and Waiguan. The aim of Tui Na manipulation was to relieve the inflammatory reaction around the tendon sheath, promote blood circulation and improve local function. Each intervention lasts 20-30 minutes, twice a week for 4-8 weeks.
Study NCT06709911 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Blood flow restriction training
Description: This group used pressurized blood flow restriction training, in which the proximal part of the temporal joint was pressurized by a pressurized device to restrict blood flow. The training consisted of low-load wrist flexion and extension, fist clenching and unclenching, and wrist rotation. The training intensity was set at 20%-50% 1RM, and the frequency was 2 times per week for 4 to 8 weeks. Pressurization was performed before training and the pressure was set in the range of 20-50 mmHg, and the training period was supervised by a professional.
Study NCT06709911 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Magnetic Bead Pressure Stimulation and Tui Na Manipulation Combined Intervention
Description: This group received the combined intervention of magnetic bead pressure stimulation and Tui Na manipulation. Before treatment, the magnetic beads were applied to specific acupoints on the hand (e.g., Hegu, Ahshi, Waiguan, etc.), fixed by breathable patches, and combined with Tui Na manipulation. During Tui Na, the magnetic beads are pressed and kneaded to further enhance the stimulation effect of the acupoints. After Tui Na, the magnetic beads remain in the affected area and can be pressed and kneaded 2-3 times a day for 3 minutes each time to produce a slight sensation of soreness and distension. The aim of the massage is to relieve the inflammatory reaction around the tendon, loosen muscle tension and tendon sheath adhesions and promote blood circulation and joint mobility. The cycle of intervention is 4 to 8 weeks.
Study NCT06711302 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham RIC
Description: Remote Ischemic Conditioning is given twice a day with 60mmHg pressure.
Study NCT05903339 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: V3G CH848 Pr-NP1 100mcg
Description: (100 mcg)
Study NCT06711302 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Remote Ischemic Conditioning treatment instrument
Description: Remote Ischemic Conditioning is given twice a day with 200mmHg pressure.
Study NCT06284902 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fexofenadine HCl Coated tablet
Description: Film-coated tablet.
Study NCT06284902 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fexofenadine HCl New Formulation Tablet
Description: New formulation tablet.
Study NCT06402331 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FPI-2265
Description: PSMA ligand radiolabeled with Ac225
Study NCT06597513 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: auto-HSCT-Supported Dose-Dense Chemotherapy With Adebrelimab
Description: Induction:~Two 21-day cycles of standard-dose etoposide 80-100 mg/m² on days 1-3 and carboplatin AUC 5-6 on day 1.~Those without disease progression will advance to consolidation treatment.~Consolidation:~Stem cell mobilization with G-CSF will be start when white blood cell count is at its nadir post-chemotherapy.~After recovery, peripheral blood stem cells will be collected via apheresis, evaluated, and cryopreserved if adequate.~Dose-dense etoposide 160-200 mg/m² on days 1-3 and carboplatin AUC 10-12 on day 1 for two 21-day cycles.~Within 48-72 hours after the first cycle, autologous peripheral blood stem cells will be reinfused with G-CSF.~Further consolidation will depend on hematopoietic recovery with standard-dose EC plus adebrelimab 1200 mg on day 1 for four 21-day cycles.~Maintenance:~Adebrelimab 1200 mg every 21 days will be given until disease progression, intolerable toxicity, death, patient withdrawal, or investigator decision.
Study NCT06713083 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Specifically designed and structured exercise program (based on resistance/strength, designed to be executed in bed or minimal mobility). It is an adaptation from the exercise program described by Brun CR et al (Brun CR, Shoemaker JK, Bocking A, Hammond JA, Poole M, Mottola MF. Bed-rest exercise, activity restriction, and high-risk pregnancies: a feasibility study. Applied Physiology, Nutrition, and Metabolism. 2011;36(4):577-582).
Study NCT06714084 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neoadjuvant Chemotherapy (NACT)
Description: Two cycles of carbonilumab plus TP regimen neoadjuvant chemotherapy will be implemented to patients with advanced cervical cancer
Study NCT06714084 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: maintenance therapy
Description: one years of maintenance therapy with carbonilumab alone will be implemented to patients with advanced cervical cancer receiving standard concurrent chemoradiotherapy
Study NCT06714474 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Simulation Game
Description: The Virtual Simulation Game (VSG) is an interactive, scenario-based digital training tool designed to enhance venous blood sampling (VBS) skills. Participants engage with the VSG platform to complete modules that simulate real-life clinical scenarios, allowing them to refine decision-making and procedural skills in a safe, controlled environment. This intervention is used in addition to traditional training to reinforce learning through repetition and feedback.
Study NCT06714474 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Training
Description: Traditional training consists of theoretical instruction and hands-on practice sessions conducted in a laboratory setting. Participants observe VBS demonstrations, followed by supervised practice on peers to develop their procedural skills. This intervention represents the standard educational approach for VBS and serves as the comparator in this study.
Study NCT06714474 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traditional Training
Description: Traditional training consists of theoretical instruction and hands-on practice sessions conducted in a laboratory setting. Participants observe VBS demonstrations, followed by supervised practice on peers to develop their procedural skills. This intervention represents the standard educational approach for VBS and serves as the comparator in this study.
Study NCT06713915 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Contrast-Enhanced Mammography
Description: Only patients in the prospective cohort will undergo CEM in addition to breast ultrasound.
Study NCT06713733 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: local infiltration
Study NCT06713733 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chymotrypsin
Description: orally given
Study NCT06712953 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: the peer assessment group
Description: Students in the peer assessment group were paired (by randomization, on their request) to have a teammate of the same sex before the extremity examination experience. In the following process, the students were asked to perform extremity examinations in line with the specified objectives. Students in the standardized patient group were asked to perform extremity examinations per the specified objectives in standardized patient.
Study NCT06712160 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Artificial Intelligence
Description: The number of canals detected by AI
Study NCT06712875 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib and Nivolumab
Description: Trametinib combined with nivolumab (Cohort A)
Study NCT06712875 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib, trametinib, nivolumab
Description: Dabrafenib + trametinib combined with nivolumab (Cohort B)
Study NCT06713161 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: NIR-II Probe(i.e ICG-POL6326) incubation solution
Description: After the tissues were incubated with the optimal concentration of the NIR-II probe for the appropriate time, the tissues were washed with the eluate, and then the fluorescence intensity of different tissues was detected to evaluate whether the tissues had cancer tissue invasion.
Study NCT06710561 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPN01 for Injection
Description: After each subject was randomly assigned, different doses of SPN01 for Injection (0.02 mg/kg, 0.06 mg/kg, 0.12 mg/kg) were administered intravenously in a single dose.
Study NCT06710561 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: After each subject was randomly assigned, a single intravenous injection of 0.9% sodium chloride was administered
Study NCT06710561 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPN01 for Injection
Description: Colorectal cancer subjects will receive intravenous injection of SPN01 0.06 mg/kg for a single dose.
Study NCT06710574 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-RBD
Description: Bifidobacterium triple viable capsule (Bifico Capsule, Shanghai Shangyao Xinyi Pharmaceutical Factory Co., LTD.) 420mg, two times a day, 4 capsules each time; At the same time give the bacillus licheniformis living bacterium capsule (whole bowel capsule, northeast pharmaceutical) 0.5 g, three times a day, two at a time, keep the original anti Parkinson's drugs
Study NCT06710574 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: iRBD
Description: Bifidobacterium triple viable capsule (Bifico Capsule, Shanghai Shangyao Xinyi Pharmaceutical Factory Co., LTD.) 420mg, two times a day, 4 capsules each time; At the same time give the bacillus licheniformis living bacterium capsule (whole bowel capsule, northeast pharmaceutical) 0.5 g, three times a day, two at a time.
Study NCT06512597 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Primary Intervention for Combination Therapy - IBD Coping Strategies Program
Description: psychosocially credible treatments each comprised of seven 45-minute sessions over a 12-week period, delivered via telemedicine.
Study NCT06512597 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Time and Attention Control - IBD Support Program
Description: psychosocially credible treatments each comprised of seven 45-minute sessions over a 12-week period, delivered via telemedicine.
Study NCT06713681 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: TTP-ICG incubation solution
Description: Fresh breast massed and lymph nodes will be incubated with TTP-ICG with different concentrations and times